This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Heart failure with preservedejectionfraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still limited, indicating our ongoing incomplete understanding on the underlying molecular mechanisms.
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 million adults in the U.S.
Among a cohort of multiethnic participants without baseline cardiovasculardisease, the presence of extracoronary calcification (ECC) at baseline was independently associated with an increased risk for heart failure (HF), especially HF with preservedejectionfraction (HFpEF).
Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovasculardisease and ways to integrate them into daily practice. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”
Emerging evidence suggests that vascular stress from cardiovascular-related co-morbidities promotes microvascular dysfunction, a key component in the development of heart failure with preservedejectionfraction.
In the long term, a history of gestational hypertension and pre-eclampsia significantly increases the risk of future cardiovasculardisease including chronic hypertension, coronary artery disease, heart failure and stroke.
BMI, body mass index; CV, cardiovascular; CVD, cardiovasculardisease; HELLP, haemolysis, elevated liver enzymes, low platelet count. Abstract During pregnancy, the maternal cardiovascular (CV) system undergoes major haemodynamic alterations ensuring adequate placental perfusion and a healthy pregnancy course.
Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preservedejectionfraction. However, the association of EAT thickness with the development of cardiac dysfunction in subjects with severe obesity without known cardiovasculardisease is unclear.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] 5, 6] So, it seems that once cardiovasculardisease is present, then obesity may offer some degree of protection.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovasculardisease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preservedejectionfraction (HFpEF) and type 2 diabetes.
Award Winners: Arquivos Brasileiros de Cardiologia Best Original Article – Determining Percentiles of Atherosclerotic Cardiovascular Risk According to Sex and Age in a Healthy Brazilian Population Authors: Fernando Yue Cesena, Nea Miwa Kashiwagi, Carlos Andre Minanni, Raul D.
Cardiovasculardisease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovasculardisease in women continues to be underrepresented and undertreated.
Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preservedejectionfraction (HFpEF).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content